<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>From Dr</title></head><body><div><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">WHO Collaborating Centre for Reference and Research on Influenza</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (AMR0007)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">I write as director of the WHO Collaborating Centre for Reference and Research on Influenza (WHO CC) based at the MRC National Institute for Medical Research, Mill Hill, London. The WHO CC in London is one of six WHO CCs; others are located in Atlanta, USA; Memphis, USA; Melbourne, Australia; Tokyo, Japan and Beijing, China. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The role of the six WHO CCs is to build up a global picture of the risk of influenza and advise national and international authorities on the risk of influenza, on any changes to the properties of virus that might required changing virus strains in the influenza vaccine or any change in the likely efficacy of antiviral medicines. To do this the WHO CCs work within the WHO Global Influenza Surveillance and Response System that has 141 National Influenza Centres in 111 UN member states. National Influenza Centres share with the WHO CCs representative and unusual influenza viruses and information about influenza in their regions. The WHO CCs in collaboration with National Influenza Centres also assess the risk of zoonotic infection from influenza viruses from animals that have the potential to cause and influenza pandemic.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Many, but not all, National Influenza Centres monitor for drug resistant influenza viruses for both surveillance and direct clinical needs. WHO CCs supplement this national surveillance by testing all viruses received at the WHO CC for resistance to antiviral medicines.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There are two classes of antiviral medicines that can be effective against influenza: the adamantane drugs, amantadine and rimantadine, that act to inhibit the M2-ion channel protein of influenza viruses, and the neuraminidase inhibitors, oseltamivir and zanamivir, that inhibit the sialidase activity of the virus neuraminidase. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Seasonal influenza viruses are of two viruses types. Influenza A and Influenza B. Influenza A viruses circulate as two antigenically distinct sub-types H3N2 viruses, which have circulated and evolved in humans since 1968, and H1N1pdm09 viruses, which have circulated in humans since the swine influenza pandemic of 2009. Neither of the influenza A viruses are susceptible to the adamantane drugs, and are resistant. The adamantane drugs are not effective against influenza B viruses. Resistance to the adamantane drugs evolved in H3N2 viruses during the early 2000s and the H1N1pdm09 virus has been resistant since its introduction into the human population. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Animal viruses that pose a zoonotic and pandemic threat show variable levels of resistance to the adamantane drugs.  It is notable that many swine influenza viruses show resistance to the adamantane drugs and many H5N1 viruses also show resistance. Whether resistance in these viruses originates in the use of these drugs is far from certain. Resistance might be a natural trait and so any pandemic virus might enter the human population resistant to the adamantane drugs. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Reliance on the adamantane drugs to combat potentially pandemic influenza is not a recommended option.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The neuraminidase inhibitors are effective inhibitors of both influenza A and influenza B viruses. Resistance to oseltamivir is not common and resistance to zanamivir seems to be rare.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The H1N1 viruses that circulated circulating prior to their displacement from circulation by the H1N1pdm09 viruses had acquired resistance to oseltamivir in the 2007 - 2008 northern hemisphere winter influenza season (Hauge et al. Emerging Infectious Diseases 15, 155-162). The emergence seemed not to be associated with widespread use of oseltamivir but is likely to have arisen from the natural evolution of the virus neuraminidase glycoprotein. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Oseltamivir resistance of currently circulating H1N1ppdm09 viruses received at the WHO Collaborating Centre at NIMR is running at a levels of around 0.5% of viruses. The number of oseltamivir resistant H3N2 viruses is similarly low. These numbers cannot be taken as true estimates of the prevalence of drug resistant viruses since drug resistant viruses are more likely to be sent form the National Influenza Centres to the Collaborating Centre for further characterisation. In recent months all H1N1pdm09 and H3N2 viruses have been sensitive to zanamivir. Similarly only a low level of resistance of circulating influenza B viruses to oseltamivir and zanamivir has been detected.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Resistance has been found in viruses from patents treated Oseltamivir is used more frequently than zanamivir due the ease with which it is delivered. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There is evidence emerging that rapid use of oseltamivir has therapeutic value when used early after admission to hospital of patients with severe influenza. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">New derivatives of neuraminidase inhibitors have been developed (e.g. peramivir and laninamivir). These are designed to have improved pharmacokinetic properties or improved or alternative methods of delivery. However, viruses resistant to oseltamivir are usually also resistant to peramivir. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Levels of resistance to oseltamivir and zanamivir in animal influenza viruses appears to be low but in light of the emergence of resistance to oseltamivir in human H1N1 viruses in 2007-2008 in the absence of selection through use of the drug it is possible that a similar situation could occur in animal viruses. If these animal viruses were widespread they could compromise treatment of persons with zoonotic infections from such a virus and should the resistant virus become pandemic treatment of cases would be hugely compromised.    </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There is a clear need to develop and licence new anti-influenza medicines based on alternative virus or cellular targets. Examples being assessed currently  include T-705 and DAS181. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In summary, currently there is a single class of antiviral  medicines for influenza, the neuraminidase inhibitors, that are effective against human influenza. Resistance to the most commonly used antiviral medicine, oseltamivir, can arise on treatment with the drug or as a natural variant of the virus. Development of new classes of effective anti-influenza antiviral medicines is a priority for limiting the impact of epidemic and pandemic influenza. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p></div></body></html>